SonaCare Medical to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Novel SonaSurgery Treatment, Using “Sound Based Therapy,” Will Be Introduced
CHARLOTTE, N.C., Jan. 7, 2014 /PRNewswire/ — SonaCare Medical, LLC (SonaCare Medical), a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, will present at the upcoming J.P. Morgan Healthcare Conference being held in San Francisco, CA. Michael Klein, Chief Executive Officer of SonaCare Medical, will present on Tuesday, January 14, 2014 at 4:30 p.m. PST.
SonaCare Medical is a privately held, venture-backed world leader in minimally invasive focused ultrasound technologies; a technology that focuses sound for ablative purposes much like a magnifying glass focuses light. SonaCare Medical manufactures, and has commercialized in over 30 countries, medical devices used for the treatment of cancer and other proliferative diseases.
Historically, the company has focused on developing technologies for urologic indications that target and treat cancer precisely while avoiding surrounding tissue, thus improving both outcomes and associated quality of life. These technologies have been validated in over a dozen peer reviewed articles and studies. Recently, SonaCare Medical has expanded its surgical ablative platform from urology to a broader range of general surgical indications, in the process introducing a novel, integrated next generation system of surgical care, called “SonaSurgery.” SonaSurgery is a transformational technology that will define the future of disease focused targeted surgery through the use of fused multimodality images to guide a preplanned thermal ablative procedure performed in a robotic manner to any organ in the body.
Traditional therapeutic options have been tilted towards resection or destruction of the whole organ or gland; SonaSurgery aims to destroy only that portion of an organ or gland that is diseased. This is an approach to soft tissue ablation that combines imaging, targeted therapy, and real time dynamic tracking through an advanced robotically controlled delivery system. It integrates revolutionary technologies and clinical concepts to create a near bloodless, and in many cases incision-less, approach to soft tissue ablation.
SonaSurgery is positioned ideally for the new realities of healthcare economics via its lower acquisition cost, lower cost in use and multiple indication applicability. The technology is both a replacement for, as well as complementary to, existing and more costly traditional procedures such as radiation therapy and surgical excision. SonaSurgery will help physicians reduce complication rates and procedure times, while lowering hospital costs, for a wide range of clinical conditions. In the case of prostate cancer, for example, SonaCare Medical has been at the forefront of what is now considered “a lumpectomy for men,” thereby realizing the goal of cancer control while avoiding high rates of impotence and incontinence.
SonaCare Medical has assembled an innovative management team of veterans from imaging, radiation therapy, surgery and urology to bring “best of breed” practice and technology to its offering. The company’s engineering and manufacturing is located in Indianapolis, IN and the business is headquartered in Charlotte, NC.
About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures HIFU medical devices, including the following: Sonablate(®) 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate(®) 500 which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm(®) laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(®) 450 or 500. In the event Sonablate(®) 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S.
SOURCE SonaCare Medical, LLC